KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adient (ADNT) Capital Expenditures (2016 - 2025)

Adient (ADNT) has disclosed Capital Expenditures for 11 consecutive years, with $65.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 1.56% year-over-year to $65.0 million, compared with a TTM value of $246.0 million through Dec 2025, down 10.55%, and an annual FY2025 reading of $245.0 million, down 7.89% over the prior year.
  • Capital Expenditures was $65.0 million for Q4 2025 at Adient, down from $79.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $79.0 million in Q3 2025 and bottomed at $45.0 million in Q1 2025.
  • Average Capital Expenditures over 5 years is $62.2 million, with a median of $60.0 million recorded in 2021.
  • The sharpest move saw Capital Expenditures plummeted 41.49% in 2021, then skyrocketed 31.58% in 2023.
  • Year by year, Capital Expenditures stood at $60.0 million in 2021, then grew by 1.67% to $61.0 million in 2022, then decreased by 9.84% to $55.0 million in 2023, then increased by 16.36% to $64.0 million in 2024, then increased by 1.56% to $65.0 million in 2025.
  • Business Quant data shows Capital Expenditures for ADNT at $65.0 million in Q4 2025, $79.0 million in Q3 2025, and $57.0 million in Q2 2025.